Teresa Spencer
Family · Jackson, MSNPI 1801837026
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 732 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by GSK at 27.3% of the total. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 732 payments — averaging $21.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- AstraZeneca$3K
- Sanofi$1K
- Actelion Pharmaceuticals US, Inc.$1K
- Boehringer Ingelheim$1K
- Mallinckrodt Hospital Products Inc.$750
- plus $5K from 25 others
What the payments were for
- Food & beverage$15,87799%
- Education$1121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 213 | $4,359 |
| AstraZeneca | 71 | $2,598 |
| Sanofi | 50 | $1,336 |
| Actelion Pharmaceuticals US, Inc. | 49 | $1,212 |
| Boehringer Ingelheim | 74 | $1,119 |
| Mallinckrodt Hospital Products Inc. | 39 | $750 |
| Regeneron Healthcare Solutions, Inc. | 31 | $695 |
| Takeda Pharmaceuticals U.S.A., Inc. | 38 | $675 |
| Insmed, Inc. | 16 | $618 |
| Mylan Specialty L.p. | 21 | $382 |
| Grifols USA, LLC | 22 | $380 |
| Verona Pharma, Inc. | 20 | $280 |
| United Therapeutics Corporation | 14 | $243 |
| Amgen | 9 | $242 |
| Genentech USA, Inc. | 10 | $180 |
| Electromed, Inc. | 11 | $149 |
| Johnson & Johnson | 9 | $128 |
| Merck | 8 | $128 |
| 3b Medical, Inc. | 3 | $73 |
| Baxter Healthcare | 4 | $58 |
| Ambu Inc. | 2 | $54 |
| Gilead | 3 | $49 |
| AbbVie | 3 | $45 |
| Advanced Respiratory, Inc | 2 | $45 |
| Pulmonx Corporation | 2 | $43 |
| Viatris Specialty LLC | 2 | $41 |
| Inari Medical, Inc. | 2 | $34 |
| Philips North America LLC | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Boston Scientific | 1 | $17 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,990 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 368 | $316,892 |
| OpsumitMacitentan | 12 | $154,407 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 96 | $69,762 |
| Breo ElliptaFluticasone/Vilanterol | 113 | $61,372 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 87 | $59,254 |
| SymbicortBudesonide/Formoterol Fumarate | 112 | $34,688 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 55 | $33,197 |
| Spiriva RespimatTiotropium Bromide | 38 | $30,071 |
| EliquisApixaban | 33 | $18,621 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 291 | $12,011 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 95 | $10,276 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $9,161 |
| Ventolin HfaAlbuterol Sulfate | 84 | $6,943 |
| XareltoRivaroxaban | 12 | $6,700 |
| Arnuity ElliptaFluticasone Furoate | 20 | $5,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $4,359 | $442,983588 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,212 | $154,40712 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,598 | $104,450208 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $1,119 | $63,26993 claims |
| Johnson & JohnsonXarelto | $128 | $6,70012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Jackson
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Leondrea CollinsJackson$28K
- Elizabeth WilliamsJackson$18K
- Anna WalleyJackson$17K
- Catherine PageJackson$14K
- Mollie DotyJackson$12K
- Marty GebhartJackson$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.